Cantor Fitzgerald initiated coverage of Monopar Therapeutics (MNPR) with an Overweight rating and $74 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics initiated with a Buy at Chardan
- Monopar Therapeutics, EDNOC announce EAP for MNPR-101-Zr, MNPR-101-Lu
- Salesforce initiated, Dollar Tree upgraded: Wall Street’s top analyst calls
- Monopar Therapeutics initiated with a Buy at Lucid Capital
- Monopar Therapeutics announces inclusion in Russell 3000, Russell 2000